Biotechnology Value Fund, LP recently stated that they own a 2.1% stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) in a Form 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Thursday, September 22nd. The investor owns 399,433 shares of the stock valued at about $15,777,604. The reporting parties listed on the disclosure included Biotechnology Value Fund, LP, Biotechnology Value Fund II, LP, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd, BVF Partners LP, BVF Inc and Mark N Lampert. The disclosure is available through the SEC website at this hyperlink.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. purchased a new position in shares of Tobira Therapeutics during the first quarter worth $4,797,000. State Street Corp increased its stake in shares of Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 27,794 shares during the period. Geode Capital Management LLC increased its stake in shares of Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 799 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Tobira Therapeutics during the second quarter worth about $263,000. Finally, California State Teachers Retirement System increased its stake in shares of Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares during the period. Institutional investors own 62.02% of the company’s stock.
Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 1.07% during mid-day trading on Thursday, hitting $39.50. The company had a trading volume of 711,085 shares. The company’s market cap is $743.43 million. Tobira Therapeutics Inc. has a 12 month low of $3.76 and a 12 month high of $41.39. The firm has a 50-day moving average of $6.61 and a 200-day moving average of $8.48.
Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The company earned $1.06 million during the quarter. On average, analysts expect that Tobira Therapeutics Inc. will post ($2.65) EPS for the current year.
A number of brokerages have issued reports on TBRA. Mizuho reaffirmed a “buy” rating and issued a $305.00 target price on shares of Tobira Therapeutics in a research note on Thursday. Zacks Investment Research downgraded Tobira Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Cantor Fitzgerald downgraded Tobira Therapeutics to a “buy” rating and set a $19.00 target price for the company. in a research note on Monday, July 25th. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, June 28th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $11.00 target price on shares of Tobira Therapeutics in a research note on Wednesday, August 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Tobira Therapeutics has an average rating of “Buy” and a consensus target price of $64.79.
In related news, major shareholder A/S Novo sold 92,119 shares of the company’s stock in a transaction on Thursday, July 7th. The stock was sold at an average price of $12.20, for a total transaction of $1,123,851.80. Following the transaction, the insider now owns 2,016,691 shares of the company’s stock, valued at $24,603,630.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.20% of the company’s stock.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Want to see what other hedge funds are holding TBRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tobira Therapeutics Inc. (NASDAQ:TBRA).
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.